相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
Joshua K. Sabari et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
Chantal Pauli et al.
ONCOLOGIST (2021)
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2021)
Strategies to tackle RAS-mutated metastatic colorectal cancer
G. Patelli et al.
ESMO OPEN (2021)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Shumei Kato et al.
NATURE COMMUNICATIONS (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors
Peng Zhao et al.
ONCOLOGIST (2019)
Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome
Tilmann Bochtler et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Jason K. Sicklick et al.
NATURE MEDICINE (2019)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Jordi Rodon et al.
NATURE MEDICINE (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
K. Fizazi et al.
ANNALS OF ONCOLOGY (2019)
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site
Hidetoshi Hayashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I. Odegaard et al.
CLINICAL CANCER RESEARCH (2018)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience
Todd C. Knepper et al.
ONCOLOGIST (2017)
Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use
Cory M. Vela et al.
PHARMACOTHERAPY (2017)
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
A. M. Varghese et al.
ANNALS OF ONCOLOGY (2017)
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
Jie He et al.
BLOOD (2016)
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
K. Fizazi et al.
ANNALS OF ONCOLOGY (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site New Routes to Targeted Therapies
Jeffrey S. Ross et al.
JAMA ONCOLOGY (2015)
Prognostication in cancer of unknown primary (CUP): Development of a prognostic algorithm in 311 cases and review of the literature
Dimitrios Petrakis et al.
CANCER TREATMENT REVIEWS (2013)
Site-specific survival rates for cancer of unknown primary according to location of metastases
Kari Hemminki et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary
Richard W. Tothill et al.
JOURNAL OF PATHOLOGY (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Cancer of unknown primary site
Nicholas Pavlidis et al.
LANCET (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis
Vassilis Golfinopoulos et al.
CANCER TREATMENT REVIEWS (2009)
分享论文
